pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2496Research ArticleОБЗОРЫREVIEWЭффективность и безопасность ультрамелкодисперсного беклометазона дипропионата у больных бронхиальной астмой (Обзор литературы)Efficacy and safety of ultra-fine dispersed beclomethasone dipropionate in bronchial asthma patients (review)ЕмельяновА. В.EmelyanovA. V.
Санкт-Петербург.
Санкт-Петербургский государственный Медицинский университет им. акад. И.П.ПавловаRussian Federation20041708202105108112Copyright © Емельянов А.В., 20212021Емельянов А.В.Emelyanov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2496
.
бронхиальная астмаbronchial asthmaReferencesGlobal initiative for asthma. — NHLB/WHO Workshop report. — National Heart Lung Blood Institute, Publication number 02-3659, 2002.Global initiative for asthma. — NHLB/WHO Workshop report. — National Heart Lung Blood Institute, Publication number 02-3659, 2002.Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157 (3, pt 2): 1S-53S.Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157 (3, pt 2): 1S-53S.Suissa S., Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J. Allergy Clin. Immunol. 2001; 107 (6): 937-944.Suissa S., Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J. Allergy Clin. Immunol. 2001; 107 (6): 937-944.Suissa S., Ernst P., Benayoun S. et al. Low-dose of inhaled corticosteroids and prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332-336.Suissa S., Ernst P., Benayoun S. et al. Low-dose of inhaled corticosteroids and prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332-336.Leach C.L. Improved delivery of inhaled steroids to the large and small airways. Respir. Med. 1998; 92 (suppl. A): 3-8.Leach C.L. Improved delivery of inhaled steroids to the large and small airways. Respir. Med. 1998; 92 (suppl. A): 3-8.Goodman D., Israel E., Rosenberg M. et al. The influence of age, diagnosis and gender on proper use of metered dose inhalers. Am. J. Respir. Crit. Care Med. 1994; 150: 1256-1261.Goodman D., Israel E., Rosenberg M. et al. The influence of age, diagnosis and gender on proper use of metered dose inhalers. Am. J. Respir. Crit. Care Med. 1994; 150: 1256-1261.Kamps A.W., van Ewjil B., Roorda R.J. et al. Poor inhalation technique even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 2000; 29 (1): 39-42.Kamps A.W., van Ewjil B., Roorda R.J. et al. Poor inhalation technique even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 2000; 29 (1): 39-42.Shresthna M., Parupia H., Andrews B. et al. Metered dose inhaler technique of patients in urban ED: prevalence of incorrect technique and attempt at education. Am. J. Emerg. Med. 1996; 14 (4): 380-384.Shresthna M., Parupia H., Andrews B. et al. Metered dose inhaler technique of patients in urban ED: prevalence of incorrect technique and attempt at education. Am. J. Emerg. Med. 1996; 14 (4): 380-384.Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Respir. Med. 1998; 92 (suppl. A): 23-31.Davies R.J., Stampone P., O'Conner B.J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbone beclomethasone dipropionate at approximately half the total dose. Respir. Med. 1998; 92 (suppl. A): 23-31.Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoro-alkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343-351.Gross G., Thompson P.J., Chervinsky P. et al. Hydrofluoro-alkane-134a Beclomethasone Dipropionate, 400 mg, is as effective as chlorofluorocarbon Beclomethasone Dipropionate, 800 mg, for the treatment of moderate asthma. Chest 1999; 115 (2): 343-351.Busse W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propelent. J. Allergy Clin. Immunol. 1999; 104 (6): 1215-1222.Busse W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propelent. J. Allergy Clin. Immunol. 1999; 104 (6): 1215-1222.Firemann P, Prenner B.M., Vinsken W. et al. Long term safety and efficacy of chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann. Allergy Asthma Clin. Immunol. 2001; 86 (5): 557-565.Firemann P, Prenner B.M., Vinsken W. et al. Long term safety and efficacy of chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann. Allergy Asthma Clin. Immunol. 2001; 86 (5): 557-565.Magnussen H. E quivalent asthma control after dose reduction with HFA 134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir. Med. 2000. 94: 561-567.Magnussen H. E quivalent asthma control after dose reduction with HFA 134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir. Med. 2000. 94: 561-567.Juniper E., Price D., Stampone P.A. et al. Clinically important improvement in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate tp approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121 (6): 1824-1832.Juniper E., Price D., Stampone P.A. et al. Clinically important improvement in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate tp approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121 (6): 1824-1832.Aubier M., Wettenger R., Gans S.J. Efficacy of HFA-beclametha-sone dipropionate extra-fine aerosol (800 md/day) versus HFA-fluticasone propionate (1000 md/day) in patients with asthma. Respir. Med. 2001; 95 (1): 212-220.Aubier M., Wettenger R., Gans S.J. Efficacy of HFA-beclametha-sone dipropionate extra-fine aerosol (800 md/day) versus HFA-fluticasone propionate (1000 md/day) in patients with asthma. Respir. Med. 2001; 95 (1): 212-220.Worth H., Muir J.F., Pieters W.R. Comparison of Hydro-fluoroalkane-Beclomethasone Dipropionate AutohalerTM with Budesonide Turbuhaler TM in asthma control. Respiration 2001; 68: 517-526.Worth H., Muir J.F., Pieters W.R. Comparison of Hydro-fluoroalkane-Beclomethasone Dipropionate AutohalerTM with Budesonide Turbuhaler TM in asthma control. Respiration 2001; 68: 517-526.Thompson P., Davies R.J., Yong W.F. et al. Safety of hydroflu-oroalkane-134 a beclomethasone propionate extrafine aerosol. Respir. Med. 1998; 92 (suppl.A): 33-39.Thompson P., Davies R.J., Yong W.F. et al. Safety of hydroflu-oroalkane-134 a beclomethasone propionate extrafine aerosol. Respir. Med. 1998; 92 (suppl.A): 33-39.Reichel W.t Dahl R., Ringdal N. et al. Extrafine beclometasone dipropionate breath actuated inhaler (400 mcg/day) versus budesonide dry power inhaler (800 mcg/day) in asthma. Int. J. Clin. Pract. 2001; 55 (1): 100-106.Reichel W.t Dahl R., Ringdal N. et al. Extrafine beclometasone dipropionate breath actuated inhaler (400 mcg/day) versus budesonide dry power inhaler (800 mcg/day) in asthma. Int. J. Clin. Pract. 2001; 55 (1): 100-106.Rocca-Serra J.P., Vicaut E, Lefrancois G, Umile A. Efficacy and tolerability of new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma. Comparison with Beclomethasone CFC. Clin. Drug Invest. 2002; 22 (10): 653-665.Rocca-Serra J.P., Vicaut E, Lefrancois G, Umile A. Efficacy and tolerability of new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma. Comparison with Beclomethasone CFC. Clin. Drug Invest. 2002; 22 (10): 653-665.Lenney J., Innes J., Cropmton G.K. Inappropriate inhaler use: assessment of use and preference of seven inhalation devices. Respir. Med. 2000; 94: 496-500.Lenney J., Innes J., Cropmton G.K. Inappropriate inhaler use: assessment of use and preference of seven inhalation devices. Respir. Med. 2000; 94: 496-500.Price D., Thomas M., Mitchell G. et al. Improvement of asthma control with breath-actuated pressurized metered dose inhaler (BAI); a prescribing claims study of 5556 patients using a traditional pressurized metered dose inhaler (MDI) or breath-actuated device. Respir. Med. 2003; 97 (1): 12-19.Price D., Thomas M., Mitchell G. et al. Improvement of asthma control with breath-actuated pressurized metered dose inhaler (BAI); a prescribing claims study of 5556 patients using a traditional pressurized metered dose inhaler (MDI) or breath-actuated device. Respir. Med. 2003; 97 (1): 12-19.Haycox A., Mitchel G., Nizol C. et al. Cost effectiveness of asthma treatment with breath-actuated pressurized metered dose inhaler (BAI)-a prescribing claim study of 1856 patients using a traditional pressurized metered dose inhaler (MDI) or breath-actuated device. J. Med. Econom. 2002; 5 (1): 65-77.Haycox A., Mitchel G., Nizol C. et al. Cost effectiveness of asthma treatment with breath-actuated pressurized metered dose inhaler (BAI)-a prescribing claim study of 1856 patients using a traditional pressurized metered dose inhaler (MDI) or breath-actuated device. J. Med. Econom. 2002; 5 (1): 65-77.Lipworth B.J. Targets for inhaled treatment. Respir. Med. 2000; 94 (suppl. D): S13-S16Lipworth B.J. Targets for inhaled treatment. Respir. Med. 2000; 94 (suppl. D): S13-S16Edbasker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58 (suppl 4): 7-16.Edbasker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 1999; 58 (suppl 4): 7-16.Kelly H.W. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled steroids. J. Allergy Clin. Immunol. 1998; 102 (4, pt 2): S36-S5I.Kelly H.W. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled steroids. J. Allergy Clin. Immunol. 1998; 102 (4, pt 2): S36-S5I.Ganderton D., Lewis D., Davies R. Modulite®: a mean of designing the aerosol generated by pressurized metered dose inhalers. Respir. Med. 2002; 96 (suppl. D): S3-S8.Ganderton D., Lewis D., Davies R. Modulite®: a mean of designing the aerosol generated by pressurized metered dose inhalers. Respir. Med. 2002; 96 (suppl. D): S3-S8.
The authors declare that there are no conflicts of interest present.